Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10488
Title: | [3H]desGly-NH2(9)-d(CH2)5[D-Ileu2,Ileu4]AVP: an AVP V2 receptor antagonist radioligand. | Austin Authors: | Trinder, D;Stephenson, J M;Gao, X;Phillips, P A;Risvanis, John;Johnston, Colin I | Affiliation: | University of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia | Issue Date: | 12-Nov-1991 | Publication information: | Peptides; 12(6): 1195-200 | Abstract: | Binding characteristics of the selective V2 antagonist radioligand [3H]desGly-NH2(9)-d(CH2)5[D-Ileu2,Ileu4]AVP to rat kidney were determined. Binding was specific, saturable and reversible. The peptide bound to a single class of high-affinity binding sites with Bmax 69.4 +/- 6.8 fmol/mg protein and KD 2.8 +/- 0.3 nM. AVP and other related peptides displaced [3H]desGly-NH2(9)-d(CH2)5[D-Ileu2,Ileu4]AVP binding. The order of potency of inhibition was desamino-D-AVP greater than AVP greater than d(CH2)5[D-Ileu2,Ileu4]AVP greater than oxytocin greater than d(CH2)5[Tyr(Me)2]AVP greater than d(CH2)5[sarcosine7]AVP, which is typical of a selective V2 radioligand. Autoradiographic localization of [3H]desGly-NH2(9)-d(CH2)5[D-Ileu2,Ileu4]AVP binding sites in kidney showed dense binding in the inner and outer medulla with less binding in the cortex, which is consistent with known renal V2 receptor distribution. | Gov't Doc #: | 1815207 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/10488 | Journal: | Peptides | URL: | https://pubmed.ncbi.nlm.nih.gov/1815207 | Type: | Journal Article | Subjects: | Angiotensin Receptor Antagonists Animals Arginine Vasopressin.analogs & derivatives.metabolism Autoradiography In Vitro Techniques Kidney Medulla.metabolism Kinetics Membranes.metabolism Radioligand Assay Rats Receptors, Angiotensin.classification.metabolism Receptors, Vasopressin |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.